Publication

ECHELON-2 (NCT01777152), A randomized, double-blind, phase 3 study of brentuximab vedotin plus CHP vs CHOP in previously untreated patients with CD30-positive peripheral t-cell lymphoma: 5-year results

Zinzani, P. L.
Illidge, Timothy M
Horwitz, S. M.
O'Connor, O. A.
Pro, B.
Iyer, S. P.
Advani, R.
Bartlett, N. L.
Christensen, J. H.
Morschhauser, F.
... show 10 more
Keywords
Type
Article
Citation
Zinzani PL, Illidge T, Horwitz SM, O'Connor OA, Pro B, Iyer SP, et al. ECHELON-2 (NCT01777152), A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN plus CHP VS CHOP IN PREVIOUSLY UNTREATED PATIENTS WITH CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMA: 5-YEAR RESULTS. Haematologica. 2021;106(10):3-.
Journal Title
Journal ISSN
Volume Title
Embedded videos